Found 20 clinical trials
A Study of MSB0254 Injection in Advanced Solid Tumors
This study was an open, multi-dose dose escalation phase I clinical study to evaluate the safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy.
- 0 views
- 16 Feb, 2024
- 1 location
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
Approximately 100 adult participants with locally advanced, recurrent, or metastatic solid tumors will be enrolled.
- 0 views
- 16 Feb, 2024
- 2 locations
Phase Study of the HS-10241 in Patients With Advanced Solid Tumors
HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to …
- 0 views
- 05 Aug, 2020
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
- 0 views
- 16 Feb, 2024
- 4 locations
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- 0 views
- 20 Jul, 2022
- 24 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant …
- 0 views
- 16 Feb, 2024
- 1 location
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
- 0 views
- 16 Feb, 2024
- 8 locations
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- 0 views
- 16 Feb, 2024
- 1 location
A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX (cetuximab) in adults with recurrent and/or metastatic solid tumors.
- 0 views
- 05 Aug, 2020
A Phase 1 Multi-Center Safety Dose Escalation Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors
Phase 1, first-in-human, open-label dose-escalation study to determine the MTD and RP2D, and to assess the DLT of INV-1120 (also referred to as investigational product or IP). The safety, tolerability, and PK of INV-1120 will be assessed in adult patients with advanced solid tumors.
- 0 views
- 16 Feb, 2024
- 2 locations
- 1
- 2